The Wang lab is interested in developing drug leads/candidates for kinase, phosphate kinase and protein targets identified by UNC faculty and external investigators. We have successfully used the structure- and/or ligand-based drug design approaches to deliver compounds to clinic (MerTK inhibitors such as MRX-2843) or licensing (IDH1 inhibitor, co-developed with NCATs). We will continue to apply the similar approaches for drug discovery towards new targets.
Associate Professor, Chemical Biology and Medicinal Chemistry
Director of Medicinal Chemistry
Ivie Conlon, PhD
Shiva Guduru, PhD
Megan Hopkins, PhD
Deyu Kong, PhD
Yubai Zhou, PhD